

**In the claims:**

1. (Currently Amended) An isolated antibody or functional fragment thereof which binds with ~~(e.g. to)~~ and neutralises human ~~NOGO~~ NOGO-A wherein said antibody or functional fragment thereof comprises each of the following CDRs:

Light chain CDRs set forth in SEQ ID NOs: 1, 2, and 3 and

Heavy chain CDRs set forth in SEQ ID NOs: 4, 5, and 6

or an analog of any CDR wherein the amino acid sequence of said CDR is modified by one amino acid.

2. (Currently Amended) An isolated antibody according to claim 1 which binds to a ~~region of human NOGO-A protein between amino acids 586 to 785~~ SEQ ID NO: 87.

3. (Currently Amended) An isolated antibody according to claim 2 which binds to a ~~region of human NOGO-A between amino acids 586 to 685~~ the amino acid sequence: MQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSV NYESIKHEPENPPPYEEAMSVSLKKVSGIKEEIKEPENINA.

4. (Withdrawn) An antibody according to claim 2 which binds to a region of human NOGO-A between amino acids 686 to 785

5. (Currently Amended) An isolated antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs: ~~SEQ.I.D.NO:~~ set forth in SEQ ID NOs: 1, 2, and 3 and

Heavy chain CDRs: ~~SEQ.I.D.NO:~~ set forth in SEQ ID NOs: 4, 5, and 6.

6. (Withdrawn) An antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs: SEQ.I.D.NO:7, 8 and 9

Heavy chain CDRs: SEQ.I.D.NO:10, 11 and 12.

7. (Withdrawn) An antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs:SEQ.I.D.NO:13, 14 and 15;

Heavy chain CDRs: SEQ.I.D.NO:16, 17 and 18.

8. (Cancelled).
9. (Withdrawn) An antibody according to claim 6 which comprises a heavy chain variable domain which comprises each of the CDRs selected from CDRH1, CDRH2 and CDRH3 and a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.
10. (Withdrawn) An antibody according to claim 7 which comprises a heavy chain variable domain which comprises each of the CDRs selected from CDRH1, CDRH2 and CDRH3 and a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.
11. (Currently Amended) An isolated antibody of claim 1 which is a monoclonal antibody.
12. (Currently Amended) An isolated antibody of claim 1 which is a humanised or chimeric antibody.
13. (Currently Amended) An isolated antibody according to ~~claim 8~~ claim 1 wherein the heavy chain variable region comprises the amino acid sequence set forth in ~~SEQ.I.D.NO:37~~ SEQ ID NO: 37.
14. (Withdrawn) An antibody according to claim 9 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ.I.D.NO:38.
15. (Withdrawn) An antibody according to claim 10 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:39.
16. (Currently Amended) An isolated antibody according to ~~claim 8~~ claim 1 wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

17. (Withdrawn) An antibody according to claim 9 wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:41.
18. (Withdrawn) An antibody according to claim 10 wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:42.
19. (Currently Amended) A pharmaceutical composition comprising an isolated anti-NOGO antibody or functional fragment thereof according to claim 1 together with a pharmaceutically acceptable diluent or carrier.
20. (Withdrawn) The method of treatment or prophylaxis of stroke and other neurological diseases/disorders in a human which comprises administering to said human in need thereof an effective amount of an anti-NOGO antibody, according to claim 1, including altered antibodies or a functional fragment thereof.
21. (Cancelled)
22. (Withdrawn) The method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease/disorder which comprises administering to said human in need thereof an effective amount of an anti-NOGO antibody according to claim 1, including altered antibodies or a functional fragment thereof.
23. (Cancelled)
24. (Withdrawn) The method of treating or prophylaxis of stroke or other neurological disease/disorder in a human comprising the step of parenteral administration of a therapeutically effective amount of an anti-NOGO antibody according to claim 1 to said human.
25. (Withdrawn) The method of claim 24 wherein the anti-NOGO antibody is administered intravenously.

26. (Withdrawn) The method of claim 20 wherein the other neurological disease/disorder is selected from the group consisting of;  
traumatic brain injury, spinal cord injury, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease and multiple sclerosis.

27. (Withdrawn) The method of promoting axonal sprouting comprising the step of contacting a human axon with an anti-NOGO antibody of claim 1.

28. (Withdrawn) The method of claim 27 wherein the method is in vitro.

29. (Withdrawn) The method of producing an anti-NOGO antibody of claim 1 which specifically binds to and neutralises the activity of human NOGO-A which method comprises the steps of;

- (a) providing a first vector encoding a heavy chain of the antibody;
- (b) providing a second vector encoding the light chain of the antibody;
- (c) co-transfecting a mammalian host cell with said first and second vectors;
- (d) culturing the host cell of step (c) in culture media (preferably serum free) under conditions permissive to the secretion of the antibody from said host cell into said culture media;
- (e) recovering the secreted antibody of step (d).

30. (Withdrawn) The method of producing an anti-NOGO antibody that competitively inhibits the binding of the antibody of claim 1 which method comprises the steps of;

- (a) providing a first vector encoding a heavy chain of the antibody;
- (b) providing a second vector encoding the light chain of the antibody;
- (c) co-transfecting a mammalian host cell with said first and second vectors;
- (d) culturing the host cell of step (c) in culture media (preferably serum free) under conditions permissive to the secretion of the antibody from said host cell into said culture media;
- (e) recovering the secreted antibody of step (d).

31. (Withdrawn) The method of producing an intravenously administrable pharmaceutical composition comprising an anti-NOGO antibody which binds to and neutralises the activity of NOGO-A which method comprises the steps of;

- (a) providing a first vector encoding a heavy chain of the antibody;
- (b) providing a second vector encoding the light chain of the antibody;
- (c) introducing (e.g.co-transfecting) said first and second vectors into a mammalian host cell;
- (d) culturing the host cell of step (c) in culture media (preferably serum free) wherein said host cell secretes into said culture media an antibody comprising a light and heavy chain;
- (e) recovering (and optionally purifying) the secreted antibody of step (d);
- (f) incorporating the antibody of step (e) into a intravenously administrable pharmaceutical composition.

32. (Withdrawn) The method of producing an anti-NOGO antibody which binds to human NOGO-A between amino acids 586-785, particularly 586-685 or 686 to 785 and neutralises the activity of said NOGO-A which method comprises the steps of;

- (a) providing a first vector encoding a heavy chain of the antibody;
- (b) providing a second vector encoding the light chain of the antibody;
- (c) introducing (e.g.co-transfecting) said first and second vectors into a mammalian host cell;
- (d) culturing the host cell of step (c) in culture media (preferably serum free) wherein said host cell secretes into said culture media an antibody comprising a light and heavy chain;
- (e) recovering (and optionally purifying) the secreted antibody of step (d);

33. (Withdrawn) The method according to claim 29 wherein the host cell is selected from the group consisting of; NS0 Sp2/o, CHO, COS, a fibroblast cell such as 3T3, particularly CHO.

34. (New) An isolated functional fragment of the antibody according to claim 1 which binds to SEQ ID NO: 87.

35. (New) An isolated functional fragment of the antibody according to claim 34 which binds to the amino acid sequence:

MQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSV  
NYESIKHEPENPPPYEEAMSVSLKKVSGIKEEIKEPENINA.

36. ((New) An isolated functional fragment of the antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs set forth in SEQ ID NOs: 1, 2, and 3 and

Heavy chain CDRs set forth in SEQ ID NOs: 4, 5, and 6.